“…Higher Txnip expression levels are associated with better prognosis in breast cancer patients as measured by the metastasis-free interval after initial treatment (31). Txnip down-regulation promotes carcinogenesis, and Txnip is downregulated in many different forms of cancer, including breast, prostate, colorectal, gastric, kidney, liver cancer, squamous cell carcinoma, melanoma, pheochromocytoma, HTLV-1 infected T cells, B-cell and Hodgkin lymphoma, and acute lymphoblastic and chronic lymphocytic leukemia (4,73,77,82,93,158,193,210,217,273,276,278,296,304,307).…”